New and Revised Draft GMP Guidances FDA is planning to publish 2017
Recommendation

2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has published a Guidance Agenda with planned new and revised Draft Guidances for the calendar year 2017. Amongst these documents are a few which might be interesting for the GMP area, for example:
- Bioanalytical Method Validation; Revised Draft
- Container Closure Systems for Packaging Human Drugs and Biologics; Revised Draft
- Drug Master Files; Revised Draft
- Visual Inspection of Injectable Drug Products
- Current Good Manufacturing Practice for Medical Gases; Revised Draft
- Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products; Revised Draft
- Field Alert Report Submission
- Repackaging of Certain Drug Products by Pharmacies and Outsourcing Facilities
The items of the Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2017 reflect draft and revised draft guidances under development as of the date of FDA's posting. So there might be more to come.
Related GMP News
15.07.2026Root Cause Analysis and CAPA: Two more Warning Letters issued to Companies in Europe
01.07.2026EMA publishes updated Q&A on EU-US MRA - Veterinary Medicinal Products now fully covered
24.06.2026Reduced Testing a Matter of GMP or Specification?
17.06.2026FDA adopts updated ICH Q8/Q9/Q10 Questions & Answers (R5)
10.06.2026European QP Association Developments January through April 2026
15.04.2026ICH Q9 Training Package updated


